Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 20, 2014Journal of Clinical Oncology

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAsim AminCarolinas Healthcare SystemEPElizabeth R. PlimackFox Chase Cancer CenterJIJeffrey R. InfanteRutgers, The State University of New Jersey

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Amin et al. (2014) studied this question.

synapsesocial.com/papers/6a169fcbe7ef30cd17b24a7ehttps://doi.org/10.1200/jco.2014.32.15_suppl.5010
View Full Paper
Ask AI
Bookmark
Share